Kathryn Romano - Feb 28, 2024 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Signature
/s/ Kathryn Romano
Stock symbol
KRYS
Transactions as of
Feb 28, 2024
Transactions value $
-$768,756
Form type
4
Date filed
3/1/2024, 08:16 PM
Previous filing
Feb 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Options Exercise $33.2K +523 +4.04% $63.55 13.5K Feb 28, 2024 Direct F1
transaction KRYS Common Stock Sale -$85.3K -523 -3.89% $163.13 12.9K Feb 28, 2024 Direct F1, F2
transaction KRYS Common Stock Options Exercise $47.3K +744 +5.75% $63.55 13.7K Feb 28, 2024 Direct F1
transaction KRYS Common Stock Sale -$122K -744 -5.44% $164.60 12.9K Feb 28, 2024 Direct F1, F3
transaction KRYS Common Stock Options Exercise $8.26K +130 +1% $63.55 13.1K Feb 28, 2024 Direct F1
transaction KRYS Common Stock Sale -$21.5K -130 -0.99% $165.22 12.9K Feb 28, 2024 Direct F1, F4
transaction KRYS Common Stock Options Exercise $6.36K +100 +0.77% $63.55 13K Feb 28, 2024 Direct F1
transaction KRYS Common Stock Sale -$16.6K -100 -0.77% $166.22 12.9K Feb 28, 2024 Direct F1
transaction KRYS Common Stock Options Exercise $44.5K +700 +5.41% $63.55 13.6K Feb 28, 2024 Direct F1
transaction KRYS Common Stock Sale -$118K -700 -5.13% $168.91 12.9K Feb 28, 2024 Direct F1, F5
transaction KRYS Common Stock Options Exercise $12.9K +203 +1.57% $63.55 13.1K Feb 28, 2024 Direct F1
transaction KRYS Common Stock Sale -$34.4K -203 -1.55% $169.47 12.9K Feb 28, 2024 Direct F1, F6
transaction KRYS Common Stock Options Exercise $6.36K +100 +0.77% $63.55 13K Feb 28, 2024 Direct F1
transaction KRYS Common Stock Sale -$17.1K -100 -0.77% $171.45 12.9K Feb 28, 2024 Direct F1
transaction KRYS Common Stock Options Exercise $40.5K +637 +4.92% $63.55 13.6K Feb 28, 2024 Direct F7
transaction KRYS Common Stock Sale -$104K -637 -4.69% $162.73 12.9K Feb 28, 2024 Direct F7, F8
transaction KRYS Common Stock Options Exercise $50K +786 +6.08% $63.55 13.7K Feb 28, 2024 Direct F7
transaction KRYS Common Stock Sale -$129K -786 -5.73% $163.49 12.9K Feb 28, 2024 Direct F7, F9
transaction KRYS Common Stock Options Exercise $102K +1.6K +12.37% $63.55 14.5K Feb 28, 2024 Direct F7
transaction KRYS Common Stock Sale -$264K -1.6K -11.01% $164.84 12.9K Feb 28, 2024 Direct F7, F10
transaction KRYS Common Stock Options Exercise $12.7K +200 +1.55% $63.55 13.1K Feb 28, 2024 Direct F7
transaction KRYS Common Stock Sale -$33.2K -200 -1.52% $166.04 12.9K Feb 28, 2024 Direct F7, F11
transaction KRYS Common Stock Options Exercise $19.1K +300 +2.32% $63.55 13.2K Feb 28, 2024 Direct F7
transaction KRYS Common Stock Sale -$50.4K -300 -2.27% $167.85 12.9K Feb 28, 2024 Direct F7, F12
transaction KRYS Common Stock Options Exercise $72K +1.13K +8.76% $63.55 14.1K Feb 28, 2024 Direct F7
transaction KRYS Common Stock Sale -$192K -1.13K -8.05% $169.10 12.9K Feb 28, 2024 Direct F7, F13
transaction KRYS Common Stock Options Exercise $13.3K +210 +1.62% $63.55 13.1K Feb 28, 2024 Direct F7
transaction KRYS Common Stock Sale -$35.6K -210 -1.6% $169.75 12.9K Feb 28, 2024 Direct F7, F14
transaction KRYS Common Stock Options Exercise $8.52K +134 +1.04% $63.55 13.1K Feb 28, 2024 Direct F7
transaction KRYS Common Stock Sale -$23K -134 -1.03% $171.66 12.9K Feb 28, 2024 Direct F7, F15

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRYS Stock Option (Right to Buy) Options Exercise $0 -2.5K -6.67% $0.00 35K Feb 28, 2024 Common Stock 2.5K $63.55 Direct F1, F16
transaction KRYS Stock Option (Right to Buy) Options Exercise $0 -5K -14.29% $0.00 30K Feb 28, 2024 Common Stock 5K $63.55 Direct F7, F16
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 2,500 shares with a limit price of $140.00 per share.
F2 The transaction was executed in multiple trades ranging from $162.825 to $163.820. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The transaction was executed in multiple trades ranging from $164.030 to $164.960. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 The transaction was executed in multiple trades ranging from $165.050 to $165.270. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5 The transaction was executed in multiple trades ranging from $168.275 to $169.190. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F6 The transaction was executed in multiple trades ranging from $169.345 to $170.000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F7 The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $145.00 per share.
F8 The transaction was executed in multiple trades ranging from $162.115 to $163.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F9 The transaction was executed in multiple trades ranging from $163.120 to $164.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F10 The transaction was executed in multiple trades ranging from $164.360 to $165.270. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F11 The transaction was executed in multiple trades ranging from $165.980 to $166.100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F12 The transaction was executed in multiple trades ranging from $167.540 to $168.010. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F13 The transaction was executed in multiple trades ranging from $168.680 to $169.500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F14 The transaction was executed in multiple trades ranging from $169.690 to $169.970. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F15 The transaction was executed in multiple trades ranging from $171.460 to $172.230. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F16 50,000 options were granted that vest in four equal annual installments with the first installment vesting on February 28, 2023.